Interview with Jean-Pierre Delwart, Chief Executive Officer, Eurogentec Belgium
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Address: Rue de Stallestraat 63/4, B-1180 Brussels,Belgium
Tel:
Web: http://www.octapharma.com/en.html
Our Group-wide mission is the safe and optimal use of human proteins.
Octapharma respects donated human plasma as a scarce and valuable resource. We meet our Mission through the use of cutting-edge, validated viral inactivation and state-of-the-art purification technologies, in order to achieve the highest production yields and manufacture medical products with the highest possible safety margins. We respect human plasma as a sparce resource for life saving therapies.
The Octapharma portfolio focuses on protein and other biopharmaceutical products derived from human plasma, in three therapeutic areas:
Haematology
Coagulation factors to treat bleeding disorders.
Intensive Care and Emergency Medicine
Plasma and blood proteins (such as albumin) used to stabilise blood circulation, restore coagulation function, and prevent shock, e.g., for heavy burns, injuries, and in surgery.
Immunotherapy
Immunoglobulins to treat immune disorders and prevent rhesus incompatibility in pregnancies.
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period…
Let us begin by getting an overview of APB’s functions & objectives and your role within the association as General Manager? The Belgian Association of Pharmacists is a federation of…
Mr Bravo, in relation to your previous career in big pharma companies, you have recently made a shift into much smaller entities including Cellerix and TiGenix. What motivated you to…
Looking into your background, we see that you have developed your career in the local industry’s top 3 players: Pfizer, AstraZeneca and Novartis until assuming your position as General Manager…
Oystershell was founded in 1979, however in 2002 the company was taken over by you and your team in a MBO. Can you tell our readers more about what motivated…
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS?…
Can you begin by giving us a brief overview of Amgen in Belgium and tell our readers more about the company’s history here? Compared to other, well-established multinationals Amgen is…
Mr. De Cuyper, can you start with a brief introduction to the federal agency for medicines and health products (famhp) and its role within the Belgium’s complex regulatory environment? We…
Looking into your background, we see that you’ve spent 8 years at pharma.be, where you were advocating the traditional drug producers. What encouraged you to head FeBelGen since 2006, representing…
In your 8 years of experience within the group, how would you classify the competitive advantages derived for the company’s unique familial ownership structure? Due to its history and strong…
See our Cookie Privacy Policy Here